FDA 483 - Vivos Therapeutics Inc. - October 28, 2022

An FDA inspection of Vivos Therapeutics Inc. in Murray, KY, revealed significant deficiencies in the firm's quality system. Observations included inadequate procedures for design changes, poorly maintained complaint files, and inconsistent documentation of corrective and preventive actions. These issues indicate a need for improved adherence to regulatory requirements for medical device manufacturing.